G1 Therapeutics, Inc.

Our mission is to discover, develop and deliver next generation cancer therapies.

Founded 2008

United States 59 employees Post-IPO Equity Total: $697.37M Biotechnology, Health and Wellness +1

G1 Therapeutics, Inc. is a commercial-stage oncology company with a goal to discover, develop and deliver next generation cancer therapies. The company is dedicated to advancing the development and commercialization of next-generation anti-cancer therapies. With a profound understanding of the biology of cancer and extensive expertise in development and commercialization, G1 aims to improve the lives of those affected by cancer. Their first commercial product, COSELA® (trilaciclib), is already in the market, and they have a robust clinical pipeline evaluating targeted cancer therapies in various solid tumors such as breast, lung, and bladder cancers. Founded in 2008, G1 Therapeutics is headquartered in Research Triangle Park, N.C. The company received a noteworthy $50.05MPost-IPO Equity investment on 17 November 2022. For more information, visit www.g1therapeutics.com and follow them on Twitter @G1Therapeutics. View their social community guidelines here.

Funding Stage	Amount	Investors	Lead Investors	Date
Post IPO Equity	$50.05M	-		17 Nov 2022
Post IPO Debt	$150.00M	-		01 Jan 2021
Post IPO Debt	$100.00M	1	Hercules Capital	01 Jun 2020
Post IPO Equity	$195.10M	1	Cowen Investment Management	21 Sep 2018
Post IPO Equity	$108.40M	-		07 Mar 2018
Series C	$47.00M	10	RA Capital Management, Franklin Templeton Venture Capital +8	11 May 2016
Series B	$33.00M	7	RA Capital Management, Hatteras Venture Partners +5	05 Feb 2015
Series A	$12.60M	3	Hatteras Venture Partners, MedImmune Ventures +1	16 Oct 2013
Debt Financing	$457.90K	-		18 Apr 2013
Venture Round	$762.88K	-		12 Oct 2012

Funding Stage

Amount

Investors

Lead Investors

Date

Post IPO Equity

$50.05M

17 Nov 2022

Post IPO Debt

$150.00M

01 Jan 2021

Post IPO Debt

$100.00M

Hercules Capital

01 Jun 2020

Post IPO Equity

$195.10M

Cowen Investment Management

21 Sep 2018

Post IPO Equity

$108.40M

07 Mar 2018

Series C

$47.00M

RA Capital Management, Franklin Templeton Venture Capital +8

11 May 2016

Series B

$33.00M

RA Capital Management, Hatteras Venture Partners +5

05 Feb 2015

Series A

$12.60M

Hatteras Venture Partners, MedImmune Ventures +1

16 Oct 2013

Debt Financing

$457.90K

18 Apr 2013

Venture Round

$762.88K

12 Oct 2012

FAQ About G1 Therapeutics, Inc.

Our mission is to discover, develop and deliver next generation cancer therapies.

G1 Therapeutics, Inc. was founded in 2008.

G1 Therapeutics, Inc. is headquartered in United States.

G1 Therapeutics, Inc. operates in Biotechnology, Health and Wellness and Platforms. Its work centres on Cancer therapies, Oncology, Anti-cancer therapies and Commercial-stage company.

G1 Therapeutics, Inc. has approximately 59 employees.

G1 Therapeutics, Inc. has completed 10 funding rounds, raising a total of $697.37M. The latest funding stage is Post-IPO Equity.

Top alternatives and competitors to G1 Therapeutics, Inc. include Turnstone Biologics, Compass Therapeutics Inc., Prescient Therapeutics, Lisata Therapeutics, Inc., ALX Oncology. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.

G1 Therapeutics, Inc. and Turnstone Biologics are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

General Information

Discover More

About G1 Therapeutics, Inc.

Funding Rounds & Investors (10)

G1 Therapeutics, Inc. Alternatives & Competitors

FAQ About G1 Therapeutics, Inc.